Background: Metaplastic breast cancer is a rare disease with little information available to guide therapy. The goals of this study were to describe the patient characteristics, systemic therapies and clinical outcomes of all patients with primary metaplastic breast cancer treated at Mayo Clinic between 1976 and 1997.
Introduction
Metaplastic carcinoma of the breast is a histologically diverse group of malignancies in which adenocarcinoma is found to co-exist with an admixture of spindle cell, squamous, chondroid or bone-forming neoplastic cells. The non-adenocarcinomatous elements can be found in varying combinations within a tumor and may be present as a microscopic focus or may dominate the histologic pattern. The degree of differentiation of the metaplastic cells can also be quite variable. Due to the highly heterogeneous nature of metaplastic breast cancer there has recently been controversy regarding the classification of these malignancies [1, 2] .
Metaplastic breast cancer is rare and accounts for less than 1% of all mammary tumors [1, 2] . Most of the larger published series have appeared in the pathology [3, 4] and surgical literature [5] . These have provided little specific information on the non-surgical treatment of this disease. The efficacy of hormonal therapy or chemotherapy in either the adjuvant or metastatic setting for metaplastic breast cancer is essentially unknown. In this study we review the Mayo Clinic experience in the systemic treatment of metaplastic breast cancer. We also review all published English-language case series containing 10 or more patients.
Patients and methods
The medical index at Mayo Clinic is a comprehensive, computerized record of all diagnoses given to patients seen at the clinic. We performed a search of the index from the time period 1976-1997 using the terms 'metaplastic breast cancer', 'breast cancer-chondroid metaplasia', 'breast cancer-sarcomatous metaplasia', 'breast cancer-spindle cell metaplasia' and 'breast cancer-squamous metaplasia'. Only patients who received at least some aspect of their clinical care at Mayo Clinic were studied. Pathology specimens sent in for consultation without the patient being seen were excluded. A total of 29 patients with untreated, primary metaplastic breast cancer were identified. One patient had metastatic disease at presentation. At initial diagnosis, all tumor specimens were reviewed by a pathologist at Mayo Clinic. Of the 29 cases, 16 had tissue available for diagnostic re-review. Tumor specimens were histologically examined, and cases were included in the review if Numbers add to more than 27 due to multiple signs at presentation.
adenocarcinomatous elements were identified admixed with spindle cell, chondroid, squamous or osseus tumor on hematoxylin and eosin stained microscope slides. Information regarding the clinical presentation, therapies administered and outcomes were abstracted from the medical record of each patient. One case was excluded based on pathologic re-review documenting pure adenocarcinoma. A second case was excluded based on a review of the clinical history which revealed a previous diagnosis of breast adenocarcinoma without metaplasia. The remaining 27 cases were included in the analysis. This study was approved by the Institutional Review Board at Mayo Clinic.
Statistical analysis
Analysis of OS and DFS was limited to the 26 patients with localregional disease at diagnosis. The distributions of OS and DFS were estimated using the Kaplan-Meier method [7] . Overall survival was defined as the time from diagnosis to death. Disease-free survival was defined as the time from diagnosis to the date of first recurrence. Patients without documented recurrent disease were censored at the last date their disease status was known when estimating the DFS distribution. Gehan's generalized Wilcoxon test for comparing survival distributions was used to assess whether any patient characteristic or tumor feature was significantly associated with OS or DFS [8] .
Survival after detection of metastatic disease was defined as the time at which metastatic tissue was first discovered until death.
Results
The characteristics of the 27 patients are presented in Table 1 . All were female. Their median age at diagnosis was 59 years, (range 39-90 years). Twelve patients were 60 years of age or older, and 14 patients were younger than 60. The median tumor size was 3.4 cm (range 0.5-7.0 cm). The most common clinical presentation was a mass which was noted in 24 (89%) patients. A modified radical mastectomy was the most common surgical procedure and was performed in 17 (63%) patients. Twenty-three patients had information available on nodal status. Among these 23 patients, three (13%) were node-positive. ER (estrogen receptor status) and PR (progesterone receptor status) information was available for a different subset of 23 patients. Three patients (13%) were both ER and PR positive. One patient was ER positive only and one was PR positive only. Among the 16 patients with tissue available for re-review, eight had pure spindle cell metaplasia and there was one case each of osseous, squamous and chondroid metaplasia. The remaining five patients had a mixture of more than one metaplastic element. Adjuvant systemic therapy was administered to 13 patients. Nine received chemotherapy either alone or with subsequent tamoxifen and/or radiation. The chemotherapeutic regimens used were; (i) doxorubicin, cyclophosphamide (AC) in four, (ii) cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in three and (iii) cyclophosphamide, doxorubicin, 5-fluorouracil (CAF) in two patients. Tamoxifen alone or combined with radiation was given to three patients and one patient received radiation therapy only. Five patients received adjuvant radiation therapy in combination with either chemotherapy and/or tamoxifen, and one patient received radiation alone.
At last follow-up, 14 patients were alive with no evidence of disease (NED), three were alive with disease, nine were dead of disease and one was dead, cause unknown. The median follow-up time for the patients who were still alive at the time of last contact was 1.7 years (range 4 days to 11.8 years). For the 26 patients with local-regional disease at diagnosis, the three-year DFS was 40% (95% CI: 23%-73%) and the three-year OS was 71% (95% CI: 51%-97%). The median disease- Time from diagnosis (years) Figure 1 . Progression-free survival for 26 women with local-regional Figure 3 . Progression-free survival according to age for 26 women metaplastic breast cancer.
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free survival time was 2.4 years ( Figure 1 ) and the median overall survival time was 6.4 years ( Figure 2 ). Prognostic factors were analyzed for the 26 patients with local-regional disease at diagnosis. These included age, estrogen receptor status, tumor size, family history and prior exogenous estrogen use. Nodal status was not examined as only three patients had axillary lymph node involvement at diagnosis. In univariate analysis, only age and prior estrogen use were found to be significantly associated to either DFS or OS. Those women greater than or equal to 60 years old at diagnosis were found to have an increased DFS time compared to those less than 60 years old at diagnosis (P = 0.011, Figure 3 ) but no difference in OS was found. Among those with a prior history of estrogen use, both DFS (P = 0.022) and OS (P = 0.003) were significantly decreased (Figures 4  and 5) . Because of the unavailability of all prognostic information, these results must be interpreted cautiously and need to be confirmed in a multivariate analysis.
Of the 26 patients with local-regional disease at presentation, 13 (50%) experienced recurrent disease and are shown in Table 2 . Ten of these thirteen patients (77%) had metastases to the lungs. Treatments for the 14 patients with metastatic disease are shown in Table 2 . Seven of the 14 patients (50%) received palliative chemo- Time from diagnosis (years) Figure 5 . Overall survival according to previous estrogen exposure for 26 women with local-regional metaplastic breast cancer.
therapy with a variety of regimens. There was one partial response to doxorubicin with a duration of four months (patient 5). The median survival after detection of metastatic disease among these 14 patients was eight months. There were no responses in four patients treated with tamoxifen. The two patients with metastases who were alive without evidence of disease at 4.9 years and 1.7 years after diagnosis (patients 9 and 12) had isolated recurrences to the chest wall (four months after primary therapy) and liver (21 months after primary therapy) treated with radiation and surgery, respectively.
Discussion
Metaplastic breast cancer is a rare disease with little published information to guide therapeutic decisions. A literature search using MEDLINE and CANCERLIT covering the years 1966-1997 retrieved 12 series published in the English language that each contained 10 or more patients [3-6, 9-16]. There were a total of 429 patients described in these reports. Of these, only 38 had received chemotherapy or hormonal therapy in the adjuvant setting and 24 had chemotherapy for metastatic disease. In many cases chemotherapeutic regimens were unspecified and in no series was information regarding response available. Our series is the first to provide detailed information on treatment regimens and patient outcome and suggests that the presentation and clinical behavior of these tumors is different from adenocarcinomas of the breast without metaplasia. Metaplastic breast cancer presents with axillary nodal involvement less frequently than adenocarcinoma of the breast. Only three of the 23 patients (13%) in our series for whom lymph node status was known had nodal disease at diagnosis. These data are consistent with previous reports which have reported incidences of axillary nodal involvement at diagnosis of metaplastic breast cancer of between 6% and 26% [3] [4] [5] [6] . The median tumor size of the patients included in our study was 3.4 cm (range 0.5-7.0 cm). Data from patients with adenocarcinoma of the breast without metaplasia suggest that for tumors ranging in size from 3.0-5.0 cm, the expected frequency of axillary node involvement is greater than 50% [17] . Of our 15 patients with tumor sizes between 3.0 and 5.0 cm, only three (20%) were node-positive.
With a median follow-up time of two years, 10 of 19 patients with local, node-negative disease in our study recurred (53%). This is consistent with previous reports, documenting recurrence of node-negative metaplastic breast cancer in 35% to 62% of patients after median 417 follow-up periods ranging from 2.3 to 5.4 years [3] [4] [5] [6] . In adenocarcinoma of the breast without metaplasia, node-negative patients with primary tumor sizes ranging between 3.0 and 5.0 cm have been found to have rates of recurrent disease of 17%-20% at five years [17] and 40%-70% at 25 years [18] . Despite metaplastic breast cancer being less likely to present with positive axillary lymph nodes, the risk of developing metastatic disease is greater than expected based on historic comparisons to typical adenocarcinoma of the breast. This supports the concept that metaplastic breast cancer is an aggressive tumor with a high risk of recurrence following primary therapy.
Previous studies [3] [4] [5] [6] 9] using arbitrary tumor size cut-offs found tumor size to be a significant risk for recurrent disease. This was not confirmed in our study when size was dichotomized at 2 cm (P = 0.34) or at the median value (P = 0.24). It is possible that this is due to the small number of patients in our study or the smaller median tumor size in our patients with local-regional disease (median 3.4 cm) as compared to these other studies (range of mean and median tumor sizes 3.9-5.0 cm).
Wargotz et al. [3] in a large series of patients with spindle cell breast carcinoma, found that only 1 of the 18 patients for whom information was available was estrogen receptor (ER) positive and 0 of 14 patients were progesterone receptor (PR) positive. In another series of patients with carcinosarcoma of the breast, only one of the 11 patients studied was positive for both ER and PR [6] . Gutman et al. [5] found 3 of 24 patients with sarcomatoid metaplastic breast cancer to be both ER and PR positive. Information about ER and PR was available for 23 patients in our study. Of these, only three patients (17%) were both ER and PR positive. One patient was ER positive only and one was PR positive only. These data are consistent with the low degree of hormone receptor expression found in previous studies and suggests that expression of ER or PR may provide little information in metaplastic breast cancer. Rosen notes that the lack of ER and PR may be due to the absence of a prominent glandular epithelial compartment in these tumors [1] .
Data on the utility of adjuvant hormonal therapy or chemotherapy in metaplastic breast cancer are limited. Wargotz et al. [3] found that 8 of 100 patients in their series received adjuvant chemotherapy or irradiation with six of these dying of disease. In their second study [6] , 7 of 12 patients who received adjuvant radiation and/or chemotherapy died of disease. Gutman et al. [5] found no significant differences in the risk of local recurrence for those treated with adjuvant radiotherapy or in the risk of distant metastases for those treated with adjuvant chemotherapy. Adjuvant therapies were administered to thirteen patients in our study. These patients ranged in age from 49 to 90 years (median age 58). Nine patients had tumors ranging in size from 2 to 5 cm, two had tumors < 2 cm, and two had tumors > 5 cm. One patient had positive lymph nodes. Seven of nine patients who were treated with chemotherapy as part of their adjuvant therapy developed recurrent disease as did three of six patients who received tamoxifen. Our data suggest that adjuvant chemotherapy with the use of 'standard' regimens for adenocarcinoma of the breast may be relatively ineffective for metaplastic breast cancer.
Patients over the age of 60 years had an improved DFS, but not OS, compared to those younger than 60 years (P = 0.011). In adenocarcinoma of the breast without metaplasia, data suggests that women under the age of 35 have a particularly poor prognosis [19, 20] . There were only two women in our study under the age of 40 (both 39 years old), one of whom recurred and died of disease 6.5 years after diagnosis and the other has been followed for less than one month. Previous studies did not find age to be a significant prognostic factor in this disease [3] [4] [5] [6] . Our data suggest that metaplastic tumors in patients younger than 60 years of age may behave more aggressively. This observation needs confirmation in a larger study that will examine all other known prognostic factors.
Unexpectedly, those with previous exposure to exogenous estrogens were observed to have a decreased DFS and OS (P = 0.022 and P = 0.003, respectively). It is possible that exogenous estrogens may stimulate the adenocarcinomatous component of a metaplastic tumor thereby resulting in a poorer DFS and OS. Unfortunately, we were unable to ascertain the duration of estrogen exposure or the proximity of estrogen use to the diagnosis of metaplastic breast cancer in our patient cohort. This result must be interpreted cautiously due to the small number of patients with a history of estrogen use in our patient cohort.
The treatments used at the onset of metastases in our patient cohort are shown in Table 2 . The median survival from detection of metastatic disease was eight months. Although the experience with systemic therapy for metastatic disease is somewhat limited, it appears that metaplastic breast cancer is less responsive to therapy with conventional regimens used for typical adenocarcinoma of the breast. Only one response (to doxorubicin) was observed in seven patients treated with a total of 14 separate trials of chemotherapy. The experience with hormonal therapy is even less but no responses were seen in the four patients treated with tamoxifen. All those treated with tamoxifen had either ER or PR positive tumors. The only patients to survive without evidence of disease after recurrence were those that could be treated with local therapies (patients 9 and 12 treated with radiation and surgery, respectively). Wargotz et al. [6] also found no survival advantage for patients treated with either chemotherapy or radiation for metastatic disease. These data suggest that patients with metastatic metaplastic breast cancer may be candidates for innovative chemotherapeutic regimens as first-line therapy for metastatic disease.
Our patient cohort demonstrated a striking tendency to develop pulmonary metastases. Eleven of 14 patients (79%) with metastases developed lung metastases at some point in their illness. Pulmonary metastases have been found to occur in 31%-70% of all patients with metastatic adenocarcinoma of the breast [21, 22] . Pitts et al. [11] found that four of five primary breast sarcoma patients with metastatic disease had lung involvement as did 7 of 12 (58%) of the patients in their study with metaplastic breast cancer. Wargotz et al. [6] found metastatic disease to the lungs to be the second most common site of recurrent disease. No patients in our cohort had bone-only metastatic disease. This fact may partly explain the observed poor prognosis for patients with metastatic disease in our study. It has been observed that patients with adenocarcinoma of the breast without metaplasia who develop bone or soft tissue only disease have an improved overall survival compared with those patients who develop visceral-only disease [23, 24] . The median survival of patients with visceral-only disease reported by Perez et al. [23] and Sherry et al. [24] was 13 months and 17 months, respectively. The eight month median survival after detection of metastatic disease in our patient cohort suggests that metastatic metaplastic breast cancer may behave in a more aggressive fashion as compared to non-metaplastic breast cancer.
Our study is limited by a number of factors. Due to the fact that metaplastic breast cancer is such a rare disease, our sample size is small. We restricted our analysis to those patients diagnosed between 1976 and 1997 in order to study the effect of conventional therapies as well as in order to have information on nodal status and hormone receptor expression. As a result of the small patient cohort, there were too few events (recurrence, death) to permit a multivariate analysis of the data. Three patients in the group who are alive without evidence of disease have been followed for less than one month and longer follow-up may change our results. Not all patients had tissue specimens available for re-review, and among those that did, there was a preponderance of specimens with pure spindle cell metaplasia. This could limit the generalizability of our results to other forms of metaplastic breast cancer. It is possible that the use of newer chemotherapeutic agents (e.g., taxanes) in the adjuvant and metastatic setting would lead to better outcomes than those reported here. Finally, our study is limited by the retrospective nature of the data retrieved.
Despite these limitations, our findings suggest the following conclusions; (i) as compared to typical adenocarcinoma of the breast, metaplastic breast cancer presents with nodal involvement and hormone receptor expression significantly less often (ii) women under the age of 60 may have a significantly decreased DFS (iii) women with prior exposure to exogenous estrogens may have a significantly decreased DFS and OS (iv) metaplastic breast cancer frequently metastasizes to the lungs (v) there may be less benefit to the use of adjuvant chemo-or hormonal therapy with standard regimens in metaplastic breast cancer as compared to adenocarcinoma (vi) the median survival for metastatic metaplastic breast cancer is shorter than that of metastatic breast cancer without metaplasia and, (vii) among the chemotherapeutic agents utilized in this patient cohort, none reliably produces responses in metastatic disease.
Further research on the mechanisms of carcinogenesis and the potential importance of newer molecular markers (e.g., p53, HER2/neu, bcl-2) will need to be performed in order to develop better prognostic factors for this disease. If our data are confirmed, patients with metaplastic breast cancer, particularly those with metastatic disease, would be appropriate candidates for clinical trials evaluating new combinations of the active chemotherapy agents for breast cancer. Considering the differences in the clinical and biologic behavior of these tumors as compared to adenocarcinomas of the breast, multi-institutional clinical trials designed specifically for metaplastic breast cancer would be useful to further characterize the biology and therapy of this disease.
